J&J closes $1 billion acquisition of Firefly Bio
The deal adds Firefly's degrader antibody conjugate platform aimed at KRAS-driven cancers and will cut J&J's 2026 adjusted EPS by about $0.46.
Johnson & Johnson announced on July 29, 2026 that it had completed its acquisition of Firefly Bio, Inc., a biotechnology company developing a proprietary degrader antibody conjugate platform called Firelink, in a deal valued at $1 billion in cash.1
The acquired technology is meant to strengthen J&J's oncology pipeline. The company said the Firelink platform expands its oncology portfolio and supports its goal of developing targeted therapies for hard-to-treat solid tumors, including KRAS-driven cancers.1 J&J described the platform's mechanism this way: it is built to send selective protein degraders to cancer cells so that the therapy acts on tumors while sparing normal tissue, addressing what the company called a shortcoming of many existing treatments.1
John Reed, J&J's Executive Vice President for Innovative Medicine Research & Development, said the completed acquisition represents a step toward new approaches for difficult-to-treat solid tumors, and that combining Firefly Bio's technology with J&J's oncology and antibody engineering expertise positions the company to develop more precise therapies, adding that J&J welcomes the Firefly Bio team.1
On the financial side, J&J said the transaction will be treated as an asset acquisition, producing an in-process research and development charge of roughly $1 billion in the third quarter of 2026.1 Separately, the company said it anticipates the deal will reduce both adjusted operational earnings per share and adjusted earnings per share by roughly $0.46 in 2026 and by roughly $0.08 in 2027.1
The same 8-K disclosed that J&J also entered into strategic agreements with Sail Biomedicines the same day, and that the combined effect of the Firefly and Sail transactions is expected to lower 2026 adjusted operational EPS and adjusted EPS by about $0.64 in total, split between roughly $0.46 from Firefly and $0.18 from Sail.1 J&J said it updated its full-year 2026 guidance to reflect these transactions relative to guidance issued on July 15, 2026.1
Written by readthrough’s AI from the linked primary sources and fact-checked against them automatically before publishing. Not investment advice.